Surya Madiraju

Co-Founder & CFO

According to a report by IMARC Group, the Indian Cell and Gene Therapy market was valued at $710.91 million in 2024 and is projected to reach $2513.14 million by 2033, exhibiting a CAGR of 15.10 percent during 202 to 2033. The market is experiencing significant growth, driven by technological advancements, increased investment and a focus on making therapies more accessible. Despite rapid growth, the market is struggling with limited access to advanced diagnostics, inconsistent data quality and a fragmented research ecosystem at the same time. Exsegen Genomics is at the forefront of solving these challenges by leveraging cuttingedge technology, deep clinical insight and a high quality genomic infrastructure to drive precision diagnostics forward.

Established in Hyderabad, Exsegen Genomics stands out for its unique platform that uses genomic information and advanced digital pathology techniques to eliminate the need for traditional tissue biopsies in brain cancer patients. The company is expanding access to safer cancer diagnostics through non-invasive, next-generation sequencing based tests, keeping pace with advances in cell and gene therapy. “With a shared mission to transform brain tumor care, we’re also focused on driving innovation that strengthens India’s biotech landscape and brings real hope to cancer patients”, says Dr Amitava Ray, Founder & CEO, Exsegen Genomics.

Personalized Treatments

Exsegen Genomics is one of the few Indian companies creating a liquid biopsy platform that uses a custom gene panel. Liquid biopsy offers a wide range of possibilities for cancer diagnosis and treatment, including tumor identification, tracking drug resistance and identifying new treatment targets. It also supports remote diagnosis through cloud-based, AI-driven algorithms that analyze unique gene patterns. These patented models greatly boost the accuracy of both diagnosing cancer and predicting how it might progress.

With access to the world’s largest private database of clinical, pathological and genomic data on brain tumors, Exsegen Genomics is well equipped than ever to tailor treatments to each patient’s needs. The company has built tech-enabled platform to keep patient’s data safe and private, following the highest standards of security. The company is driven by a proficient team that brings together deep, cross-disciplinary expertise in clinical care, scientific research, operations, technology and entrepreneurial leadership.

Integrating Tumor & Blood Genetics

Exsegen Genomics has mapped out a comprehensive approach to brain tumor diagnostics by paying close attention to every stage of the patient journey. Right from diagnosing tumors to closely tracking how the disease progresses over time, its development roadmap is designed to support better outcomes at each step. “Our end to end focused approach not only helps in safer diagnosis but also enables more personalized and responsive treatment strategies”, adds Dr Ray.

Exsegen Genomics integrates genetic data from multiple tumor and blood samples through its AI driven platform which combines machine learning with big data analytics. Leveraging advanced technologies like Next- Generation Sequencing (NGS), it’s making steady progress in uncovering the hidden layers of disease complexity.

Impactful Technology

Exsegen Genomics has established an exceptional biorepository, amassing almost 4,000 patient samples from three prestigious CTRI approved studies across India. “Our samples are carefully maintained with strict quality control measures that meet global standards. Also, 20 percent of its samples come from individuals of international backgrounds, promoting research that represents a wide range of ethnicities”, says Vikas Pawar, Co-Founder & COO, Exsegen Genomics.

Exsegen Genomics has been working under the guidance of regulatory agencies including US-FDA and CDCSO. It is aiming to roll out a CDCSO approved Liquid Biopsy test in India by the end of this year and an US-FDA approved test in the US in the first half of 2026. “Our firm’s promising early clinical results highlight that our technology is reliable and effective in understanding brain cancers and has the potential to significantly change the way brain cancers are understood and managed”, says Surya Madiraju, Co- Founder & CFO, Exsegen Genomics.

Future Ahead

Exsegen Genomics is setting its sight on the future with innovative research focused on improving brain tumor treatment outcomes. The firm is on a mission to reshape tumor diagnosis, making it more accurate and better suited to support modern cancer therapies. It is turning its wide collection of biological samples into detailed genomic data to help doctors make better treatment decisions. Furthermore, the company has also plans to partner with hospitals, universities, biotech, and pharma companies around the world. It strongly believes that such collaboration is key to position the country at the forefront of precision driven cell and gene diagnostics & therapy.